| __timestamp | Agios Pharmaceuticals, Inc. | Apellis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 2908166 |
| Thursday, January 1, 2015 | 35992000 | 6356782 |
| Friday, January 1, 2016 | 50714000 | 4303743 |
| Sunday, January 1, 2017 | 71124000 | 10463151 |
| Monday, January 1, 2018 | 114145000 | 22639184 |
| Tuesday, January 1, 2019 | 132034000 | 67046483 |
| Wednesday, January 1, 2020 | 149070000 | 139401000 |
| Friday, January 1, 2021 | 121445000 | 176771000 |
| Saturday, January 1, 2022 | 121673000 | 277163000 |
| Sunday, January 1, 2023 | 119903000 | 500815000 |
| Monday, January 1, 2024 | 156784000 |
In pursuit of knowledge
In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Apellis Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A expenses, growing by over 17,000%, from approximately $2.9 million to $500 million. This rapid escalation reflects Apellis's aggressive expansion and investment in marketing and administrative capabilities. In contrast, Agios Pharmaceuticals exhibited a more moderate growth of around 525% in the same period, indicating a more conservative approach.
These spending patterns highlight the contrasting strategies of these two biotech firms, with Apellis focusing on rapid growth and Agios maintaining steady progress. Investors and industry analysts can glean insights into each company's operational focus and market positioning through these financial trends.
Novo Nordisk A/S vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and MannKind Corporation
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.